VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians - PubMed
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians
Mohamed Hossam A Shahin et al. Thromb Haemost. 2013 Jun.
Abstract
The VKORC1 Asp36Tyr single nucleotide polymorphism (SNP) is one of the most promising predictors of high warfarin dose, but data on its population prevalence is incomplete. We determined the frequency of this SNP in participants from seven countries on four continents and investigated its effect on warfarin dose requirement. One thousand samples were analysed to define the population prevalence of this SNP. Those samples included individuals from Egypt, Ghana, Sudan, Kenya, Saudi Arabia, Peru and African Americans from the United States. A total of 206 Egyptian samples were then used to investigate the effect of this SNP on warfarin dose requirements. This SNP was most frequent among Kenyans and Sudanese, with a minor allele frequency (MAF) of 6% followed by Saudi Arabians and Egyptians with a MAF of 3% and 2.5%, respectively. It was not detected in West Africans, based on our data from Ghana, and a large cohort of African Americans. Egyptian carriers of the VKORC1 Tyr36 showed higher warfarin dose requirement (57.1 ± 29.4 mg/week) than those with the Asp36Asp genotype (35.8 ± 16.6 mg/week; p=0.03). In linear regression analysis, this SNP had the greatest effect size among the genetic factors (16.6 mg/week increase in dose per allele), and improved the warfarin dose variability explained in Egyptians (model R2 from 31% to 36.5%). The warfarin resistant VKORC1 Asp36Tyr appears to be confined to north-eastern Africa and nearby Middle-Eastern populations, but in those populations where it is present, it has a significant influence on warfarin dose requirement and the percent of warfarin dose variability that can be explained.
Figures

Populations having the variant were listed in a descending order according to the VKORC1 Asp36Tyr frequency in each studied population. Populations having the VKORC1 Asp36Tyr highest frequency were represented by dark gray color, followed by lighter gray colors in populations with lower frequency. Cross hatches represent populations in which this variant was not detected . The countries in bold italic represent the seven populations included in our study; the remainder represent previously studied populations (14-16, 21, 22, 32, 33).★ Jewish and Israeli populations include: Ashkenazi Jews (4%), Israeli Jews (1.5%), Arab Muslims in Israel (1%), Sephardic Jews (0.5%) and North African Jews (0.5%).

The box represents the values from the 25 to 75% percentile. The horizontal line represents the median. The diamond represents the mean. The vertical line extends from the minimum to the maximum value, excluding outlier and extreme values which are marked as closed circles. Nonparametric test (Mann-Whitney U test) was used to compare the warfarin dose requirements between the two groups, showing a significant difference of P = 0.03.
Similar articles
-
Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS. Ekladious SM, et al. Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3. Mol Diagn Ther. 2013. PMID: 23839801
-
Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary OA. Bazan NS, et al. Ir J Med Sci. 2014 Jun;183(2):161-72. doi: 10.1007/s11845-013-0978-y. Epub 2013 Jun 27. Ir J Med Sci. 2014. PMID: 23800980
-
Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, Cavallari LH, Perera MA. Hernandez W, et al. J Thromb Haemost. 2017 Apr;15(4):735-743. doi: 10.1111/jth.13639. Epub 2017 Mar 25. J Thromb Haemost. 2017. PMID: 28135054 Free PMC article.
-
Ndadza A, Thomford NE, Mukanganyama S, Wonkam A, Ntsekhe M, Dandara C. Ndadza A, et al. OMICS. 2019 Mar;23(3):152-166. doi: 10.1089/omi.2019.0018. OMICS. 2019. PMID: 30883300
-
Bader LA, Elewa H. Bader LA, et al. PLoS One. 2016 Dec 19;11(12):e0168732. doi: 10.1371/journal.pone.0168732. eCollection 2016. PLoS One. 2016. PMID: 27992547 Free PMC article. Review.
Cited by
-
Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE. Pratt VM, et al. J Mol Diagn. 2020 Jul;22(7):847-859. doi: 10.1016/j.jmoldx.2020.04.204. Epub 2020 May 4. J Mol Diagn. 2020. PMID: 32380173 Free PMC article.
-
Pharmacogenetics in Jewish populations.
Yang Y, Peter I, Scott SA. Yang Y, et al. Drug Metabol Drug Interact. 2014;29(4):221-33. doi: 10.1515/dmdi-2013-0069. Drug Metabol Drug Interact. 2014. PMID: 24867283 Free PMC article. Review.
-
Pharmacogenomic assessment of Mexican and Peruvian populations.
Marsh S, King CR, Van Booven DJ, Revollo JY, Gilman RH, McLeod HL. Marsh S, et al. Pharmacogenomics. 2015;16(5):441-8. doi: 10.2217/pgs.15.10. Pharmacogenomics. 2015. PMID: 25916516 Free PMC article.
-
Ali AA, Aalto M, Jonasson J, Osman A. Ali AA, et al. Sci Rep. 2020 Mar 27;10(1):5652. doi: 10.1038/s41598-020-62645-0. Sci Rep. 2020. PMID: 32221414 Free PMC article.
-
Shafique H, Ashraf NM, Rashid A, Majeed A, Afsar T, Daly AK, Almajwal A, Alruwaili NW, Khan AU, Razak S. Shafique H, et al. Front Cardiovasc Med. 2022 Jun 10;9:895169. doi: 10.3389/fcvm.2022.895169. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35757332 Free PMC article.
References
-
- Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol. 2010 Jun 22;55(25):2813–5. - PubMed
-
- Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006 Apr;79(4):291–302. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases